Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thomas

Showing results (461-470 of 791) with videos related to

Pageof 80
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2023
Response to "NGS, the New Global Standard?"Sai-Hong Ignatius Ou, Jin-Liern Hong, Petros Christopoulos, et al.
British Journal of Cancer|August 4, 2017
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancerTudor-Eliade Ciuleanu, Samreen Ahmed, Joo-Hang Kim, et al.
The European Respiratory Journal|October 13, 2012
Characteristics and outcome of patients with second primary lung cancerNiels Reinmuth, Andreas Stumpf, Patrick Stumpf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2010
Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancerLena Franziska Knoefel, Gisela Werle-Schneider, Heike Dally, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 7, 2020
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurementJan Budczies, Daniel Kazdal, Michael Allgäuer, et al.
Clinical Pharmacology in Drug Development|October 18, 2022
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy ParticipantsYing Ye, Allison Gaudy, Michael Thomas, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2025
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trialYizhe Chen, Richard A Preston, Thomas Marbury, et al.
Plos One|March 9, 2016
Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and ProgressionChiung-Kuei Huang, Yoshifumi Iwagami, Arihiro Aihara, et al.
International Journal of Oncology|January 20, 2017
AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patientsMarc A Schneider, Petros Christopoulos, Thomas Muley, et al.
Pageof 80

Showing results (461-470 of 791) with videos related to

Sort By:
Pageof 80
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2023
Response to "NGS, the New Global Standard?"Sai-Hong Ignatius Ou, Jin-Liern Hong, Petros Christopoulos, et al.
British Journal of Cancer|August 4, 2017
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancerTudor-Eliade Ciuleanu, Samreen Ahmed, Joo-Hang Kim, et al.
The European Respiratory Journal|October 13, 2012
Characteristics and outcome of patients with second primary lung cancerNiels Reinmuth, Andreas Stumpf, Patrick Stumpf, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2010
Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancerLena Franziska Knoefel, Gisela Werle-Schneider, Heike Dally, et al.
Future Oncology (London, England)|December 16, 2021
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancerByoung Chul Cho, Enriqueta Felip, Hidetoshi Hayashi, et al.
Lung Cancer (Amsterdam, Netherlands)|March 7, 2020
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurementJan Budczies, Daniel Kazdal, Michael Allgäuer, et al.
Clinical Pharmacology in Drug Development|October 18, 2022
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy ParticipantsYing Ye, Allison Gaudy, Michael Thomas, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2025
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trialYizhe Chen, Richard A Preston, Thomas Marbury, et al.
Plos One|March 9, 2016
Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and ProgressionChiung-Kuei Huang, Yoshifumi Iwagami, Arihiro Aihara, et al.
International Journal of Oncology|January 20, 2017
AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patientsMarc A Schneider, Petros Christopoulos, Thomas Muley, et al.
Pageof 80